Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.glenmarklifesciences.com | |
Market Cap | 4,784.07 Cr. | |
Enterprise Value(EV) | 4,372.34 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 34.24 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 11.40 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 183.44 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 2.13 | Calculated using Price: 390.45 |
Dividend Yield | 5.38 | Period Ending 2022-03 |
No. of Shares Subscribed | 12.25 Cr. | 122,527,172 Shares |
FaceValue | 2 | |
Company Profile | ||
The company is in the business of making high-quality drugs by unlocking the possibilities of science. |
1 Day |
|
-0.86% |
1 Week |
|
-3.54% |
1 Month |
|
-6.72% |
3 Month |
|
-6.76% |
6 Month |
|
-18.71% |
1 Year |
|
-31.71% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
5 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 451.05 | 127.84 | 60.91 | 29.87 | ||
Return on Capital Employed (%) | 527.74 | 185.60 | 96.75 | 42.24 | ||
Return on Assets (%) | -510.59 | 26.51 | 19.56 | 17.82 | 16.57 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | -1 | 88 | 402 | 753 | 2,054 | 2,143 | |
Non Curr. Liab. | 7 | 16 | 23 | 33 | 42 | ||
Curr. Liab. | 1 | 1,380 | 1,307 | 1,445 | 747 | 497 | |
Minority Int. | |||||||
Equity & Liab. | 0 | 1,475 | 1,726 | 2,221 | 2,834 | 2,681 | |
Non Curr. Assets | 545 | 565 | 598 | 706 | 797 | ||
Curr. Assets | 0 | 931 | 1,160 | 1,623 | 2,127 | 1,885 | |
Misc. Exp. not W/O | |||||||
Total Assets | 0 | 1,475 | 1,726 | 2,221 | 2,834 | 2,681 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,054 | |
Other Income | 1 | 12 | 1 | 15 | 31 | ||
Total Income | 0 | 887 | 1,549 | 1,886 | 2,138 | 2,085 | |
Total Expenditure | 0 | -639 | -1,065 | -1,294 | -1,507 | -1,476 | |
PBIDT | 0 | 248 | 484 | 592 | 631 | 609 | |
Interest | -1 | -34 | -88 | -28 | -1 | ||
Depreciation | -19 | -29 | -33 | -38 | -40 | ||
Taxation | 0 | -33 | -108 | -119 | -146 | -149 | |
Exceptional Items | |||||||
PAT | 0 | 196 | 313 | 352 | 419 | 420 | |
Adjusted EPS | -8 | 18 | 29 | 33 | 34 | 34 |
Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 10 | 195 | 388 | 598 | |
Cash Fr. Inv. | -9 | -51 | -69 | -122 | ||
Cash Fr. Finan. | 0 | 1 | -137 | -214 | -79 | |
Net Change | 0 | 2 | 8 | 106 | 397 | |
Cash & Cash Eqvt | 0 | 2 | 10 | 116 | 512 |
Sat, 28 Jan 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Audio recording of Q3 FY2022-23 Earnings Call |
Fri, 27 Jan 2023
Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2022 Pursuant to Regulations 30 and 33 of the SEBI LODR 2015 we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31 2022.The said meeting of the Board commenced at 11.00 a.m. and concluded at 12.30 p.m. The copy of the said results together with Management Discussion & Analysis Press Release and Limited Review Report of the Auditors is enclosed herewith.These are also being made available on the website of the Company at www.glenmarklifesciences.comYou are requested to take the same on record. |
Fri, 27 Jan 2023
Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31 2022<BR> <BR> Pursuant to Regulations 30 and 33 of the SEBI LODR 2015 we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31 2022. The said meeting of the Board commenced at 11.00 a.m. and concluded at 12.30 p.m. The copy of the said results together with Management Discussion & Analysis Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarklifesciences.com You are requested to take the same on record. |
Fri, 27 Jan 2023 |
|
|
|
|
|